1-3 of 3
Christopher J. Burns
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma

Clare E. Weeden, Aliaksei Z. Holik, Richard J. Young, Stephen B. Ma, Jean-Marc Garnier, Stephen B. Fox, Phillip Antippa, Louis B. Irving, Daniel P. Steinfort, Gavin M. Wright, Prudence A. Russell, Matthew E. Ritchie, Christopher J. Burns, Benjamin Solomon, Marie-Liesse Asselin-Labat
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (8): 1610–1622.
https://doi.org/10.1158/1535-7163.MCT-17-0174
Published: 02 August 2017
View article titled, Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma
Open the PDF for Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract A16: Antitumor activity of CYT997: A phase II vascular disrupting agent administered orally in combination with cisplatin in a colon adenocarcinoma xenograft model

Andrew K. Powell, Steven D. Shnyder, Patricia A. Cooper, Stuart Nelson, Christopher J. Burns, Rose Fida, Gregg D. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A16.
https://doi.org/10.1158/1535-7163.TARG-09-A16
Published: 10 December 2009
View article titled, Abstract A16: Antitumor activity of CYT997: A phase II vascular disrupting agent administered orally in combination with cisplatin in a colon adenocarcinoma xenograft model
Journal Articles

CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo

Christopher J. Burns, Emmanuelle Fantino, Ian D. Phillips, Stephen Su, Michael F. Harte, Patricia E. Bukczynska, Mark Frazzetto, Max Joffe, Irma Kruszelnicki, Bing Wang, Yue Wang, Neil Wilson, Rodney J. Dilley, Soo S. Wan, Susan A. Charman, David M. Shackleford, Rosa Fida, Cathy Malcontenti-Wilson, Andrew F. Wilks
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (11): 3036–3045.
https://doi.org/10.1158/1535-7163.MCT-09-0076
Published: 10 November 2009
View article titled, CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity <em>in vitro</em> and <em>in vivo</em>
Open the PDF for CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity <em>in vitro</em> and <em>in vivo</em> in another window